Black Creek Investment Management Inc. Trims Holdings in Grifols, S.A. $GRFS

Black Creek Investment Management Inc. lowered its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 20.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 10,045,957 shares of the biotechnology company’s stock after selling 2,523,681 shares during the period. Grifols accounts for 4.7% of Black Creek Investment Management Inc.’s investment portfolio, making the stock its 12th largest holding. Black Creek Investment Management Inc.’s holdings in Grifols were worth $100,058,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of GRFS. Brandes Investment Partners LP increased its stake in shares of Grifols by 8.9% in the second quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock worth $253,441,000 after purchasing an additional 2,294,113 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Grifols by 1.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock worth $29,948,000 after buying an additional 80,507 shares during the period. Bank of America Corp DE increased its stake in Grifols by 52.1% in the 2nd quarter. Bank of America Corp DE now owns 3,017,675 shares of the biotechnology company’s stock worth $27,280,000 after buying an additional 1,034,229 shares in the last quarter. New York State Common Retirement Fund raised its holdings in Grifols by 5.6% during the third quarter. New York State Common Retirement Fund now owns 2,589,406 shares of the biotechnology company’s stock valued at $25,790,000 after acquiring an additional 136,678 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of Grifols by 31.8% in the third quarter. JPMorgan Chase & Co. now owns 2,488,294 shares of the biotechnology company’s stock valued at $24,783,000 after acquiring an additional 600,118 shares in the last quarter.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a research report on Friday, February 6th. JPMorgan Chase & Co. cut their price objective on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a report on Monday, December 8th. Wall Street Zen cut shares of Grifols from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

Grifols Trading Down 5.0%

NASDAQ GRFS opened at $8.64 on Wednesday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.88 and a current ratio of 2.51. Grifols, S.A. has a 1-year low of $6.19 and a 1-year high of $11.14. The business has a 50 day simple moving average of $9.21 and a two-hundred day simple moving average of $9.31.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.